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Abstract: Vaccination is one of the most effective tools for limiting the impact of equine influenza (EI).
The humoral immunity established following a primary vaccination course can decrease significantly
between the second (V2) and third immunisations (V3), leaving some horses insufficiently protected
for several weeks. This so-called “immunity gap” poses a challenge to all EI vaccines. During this
period, the EI infection of vaccinated animals may be followed by marked clinical signs and virus
shedding. However, several EI vaccines have been shown to stimulate equine influenza virus
(EIV)-specific cell-mediated immunity, which is likely to play a role in protection against EIV infection
and/or mitigate the clinical and virological signs of EI. Reducing the interval between V2 and V3
has been shown to be counterproductive to longer-term immunity. Further research is needed
to define and address the “immunity gap” in horses. This study aimed to measure the level of
protection induced by a whole inactivated, ISCOMatrix adjuvanted, EI and tetanus vaccine (Equilis
Prequenza-Te) when challenged during the immunity gap (i.e., immediately before the recommended
boost immunisation, more than 5 months after V2) using infection with a recent heterologous Florida
Clade 2 (FC2) equine influenza virus (EIV) strain. This vaccine was tested in a Welsh mountain
pony model. A group of seven ponies was vaccinated twice, 4 weeks apart. The protective antibody
response was measured and ponies were challenged, along with 5 unvaccinated control ponies,
by experimental infection with the FC2 A/eq/Northamptonshire/1/13 EIV strain, 158 days (around
5.2 months) after V2 and their clinical signs and virus shedding were monitored. EI serology was
measured by single radial haemolysis (SRH) and haemagglutination inhibition (HI). Clinical signs
and virus shedding (measured by qRT-PCR and hen’s egg titration) were compared with controls.
All vaccinates had detectable, low SRH antibody titres and most had detectable, low HI titres.
Significant clinical and virological protection was observed in vaccinates (p < 0.05), supporting
the good performance of this vaccine against a recent EIV strain. In this study, the impact of
the immunity gap in ponies was limited after primary vaccination with this whole inactivated,
ISCOMatrix adjuvanted EI and tetanus vaccine (Equilis Prequenza-Te) when infected several months
after V2 with a recent FC2 strain, which is representative of EIV circulating in the EU.
Keywords: equine influenza; horse; vaccination; duration of immunity
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1. Introduction
Equine influenza (EI) is a major viral respiratory disease in horses associated with high morbidity
and potential catastrophic economic consequences [1]. To date, vaccination remains one of the most
effective methods of preventing equine influenza virus (EIV) infection (reviewed in [2]). Most
commercially available EI vaccines require a vaccination schedule that consists of two primary
immunizations (V1 and V2), usually 4 to 6 weeks apart, followed by a boost immunization (V3),
5 to 6 months after V2. Further boost vaccinations are usually administered every 6 months or 1 year,
depending of the vaccine used, the local veterinary vaccination practices, regulations, requirements
and the risk of exposure to EIV.
The efficacy of vaccines against EIV has been widely demonstrated and documented, both
in experimental infection studies in the natural host (reviewed in [2]) and/or during outbreaks
following vaccine use under field conditions [3–7]. The EI vaccines available commercially reduce the
clinical signs and virus shedding following EIV infection and do not generally produce long-lasting
sterilising immunity (i.e., protection against infection beyond what is demonstrated at or around
onset of immunity (2–3 weeks after V2)). Such protection is primarily correlated with the level
of circulating antibodies to EIV, with the single radial haemolysis (SRH) and haemagglutination
inhibition (HI) assays being suitable for measuring EIV haemagglutinin (HA)-specific antibody titres in
horses [8]. It is also important to note that most EI vaccines have been shown to stimulate EIV-specific
cell-mediated immunity [2], which is likely to play a role in protection against EIV infection and/or
in the mitigation of clinical signs and virus shedding following EIV infection. Following vaccination,
antibody titres measured by SRH have been shown to correlate well with protection against infection
following experimental or field infection. Thresholds have been defined previously for SRH antibody
titres that correlate positively with a reduction in clinical signs of EI (titres > 85 mm2) and virus
shedding (titres > 120–154 mm2) after infection with an EIV strain that is homologous to the virus
strain contained in the vaccine [9,10]. This is supported by more recent experimental EI vaccine studies
and field data [2,6].
The peaks of protective humoral immunity to EIV are usually measured 2–3 weeks after V2
and subsequent immunisations (V3, V4, etc.). However, EIV HA-specific antibody titres established
following a primary vaccination course have been shown to decrease significantly between V2 and
V3 [11,12], leaving some horses insufficiently protected and with increased susceptibility to EIV
infection for several weeks. This period of susceptibility is the so-called “immunity gap” [13] and
poses a challenge to all EI vaccines. The risk and consequences posed by the immunity gap are
not insignificant. If vaccinated horses are infected with EIV during this period, they may develop
little (mild) or no (subclinical) clinical signs of EI but may shed increased amounts of the virus.
In this condition, the risk posed to other horses, particularly naïve (unvaccinated) horses, could be
significant. This has been confirmed in recent studies [14,15], which showed that vaccinated horses
(with a vaccine containing H7N7 and H3N8 American and European lineages or H3N8 European
lineage, respectively) experimentally infected with EIV (A/equine/Richmond/1/07 Florida clade
2 sublineage or /Newmarket/1/1993 American lineage, respectively) 78 days (i.e., around 2–3 months)
after V2 and/or when SRH antibody titres were mostly below 60 mm2 could shed live infectious
EIV for several days and infect naïve sentinels. Such a risk was also clearly illustrated during the
devastating 2007 Australian EI outbreak, which was likely triggered by the importation from Japan
of horses with subclinical EIV infection [16]. According to their vaccination records, all horses had
received a primary immunisation course (V1 and V2) prior to their export to Australia. The horses
were shown to have seroconverted to EIV between the pre-export and post-arrival quarantine samples,
tending to indicate that infection occurred 2 to 4 months after V2 (i.e., during the immunity gap). More
recently, the epidemiological analysis of EI outbreaks in Ireland between 2010 and 2012 showed that
only one-third of premises affected had up-to-date vaccination records for less than one-half of the
horses present and that several vaccinated horses (vaccines contained H7N7 and H3N8 American and
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European lineage strains but did not contain Florida sublineage Clade 1 or 2 strains) had been infected
with EIV during the immunity gap (i.e., 2 to 5 months after V2) [6].
Several attempts to “close” the immunity gap have been reported. For example, a reduced
interval between V2 and V3 (e.g., 8 weeks post V2) led to lower antibody titres compared to horses
administered V3 according to the manufacturers recommendations (i.e., 24 weeks after V2) [17]. High
titres of EIV HA-specific antibody at the time of V3 may have hampered the anamnestic response
induced by boost immunisation (e.g., interference of pre-existing EI antibody response with the
EI vaccine administered) [11]. Overall, most of the evidence available indicates that product label
recommendations should be followed as far as possible, with little room available to reduce the interval
between V2 and V3 without impacting mid- and longer-term protection. In this context, the evaluation
of protection during the immunity gap is important to assess the actual risk to vaccinated horses and
in contact horses within a herd.
The study reported here aimed to measure the level of protection induced by a whole
inactivated, ISCOMatrix adjuvanted, EI and tetanus vaccine when challenged at the peak of the
immunity gap (i.e., immediately before the recommended boost immunisation, more than 5 months
after V2 in the current study) using infection with a recent Florida Clade 2 (FC2) EIV strain
(A/equine/Northamptonshire/1/13) (Table 1).
Table 1. Study design. D186 = time of experimental infection. n = number of animals;
N/1/13 = A/equine/Northamptonshire/1/13; V = vaccination; Inf. C = experimental infection;
C + 7 = 7 days after infection; C + 14 = 14 days after infection.
Group n Treatment D0 (V1) D28 (V2) D186 1
Controls 5 Placebo PBS PBS N/1/13
Vaccinates 7 Vaccination EI-TT vaccine EI-TT vaccine N/1/13
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2. Materials and Methods
2.1. Experimental Animals and Vaccination Protocol
Eligibility criteria: All 12 Welsh mountain ponies (10 males and 2 females, approximately
11 months of age) demonstrated a good health condition and were seronegative for EIV, with no
history of exposure to EIV or vaccination against EIV at the time of the study.
Setting, location and sample size: Ponies were enrolled by the study investigator. Twelve ponies
were used and housed together at the AHT premises. During the infectious period of the study (from
2 days prior to experimental infection with EIV to 14 days after infection), the 12 ponies included in
the study were assigned to 2 rooms of the category II containment facility, with 5 and 7 animals per
room, respectively. Sample size (5 control ponies and 7 vaccinated ponies) was based on the European
Pharmacopoeia criteria for EI vaccines (inactivated), which requires no fewer than 6 and 4 horses for
the treated and control groups, respectively [18].
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Investigational veterinary product (IVP) and intervention: The vaccine Equilis Prequenza Te
(MSD Animal Health, 5830 AA Boxmeer, The Netherlands IVP; lot A207B01, expiry date October 2015,
stored at 2 to 8 ◦C until use) was tested in this study. This vaccine contains the whole inactivated
EIV strains A/equine/South Africa/4/03 (H3N8, American lineage, Florida Clade 1 sublineage,
50 antigenic units) and A/equine/Newmarket/2/93 (H3N8, European lineage, 50 antigenic units),
tetanus toxoid (40 Lf), and is ISCOMatrix adjuvanted (purified saponin, cholesterol and phosphatidyl
choline). Control ponies received a negative control/placebo (CP) (phosphate buffered saline (PBS),
reference 10010-015 500 mL, lot: 1,666,825, expiry date: March 2017, stored at room temperature).
The IVP and CP were administered by deep intramuscular injection (21G × 1 12 ”, 0.8 × 40 mm needle)
in the left neck (1 dose = 1 mL) on days 0 and 28. Vaccination took place within the stated shelf-life
of the IVP/CP. On days 61 and 62, 10 male ponies were castrated. All ponies enrolled in the study
were administered 10 mL (10,000 IU) of anti-tetanus serum (Tetanus antitoxin Behring from MSD
Animal Health).
Randomisation and masking: The 12 ponies were assigned to 2 groups (control and vaccinated
groups) of 5 and 7 animals, respectively. An online randomisation generator (www.randomization.com)
was used with 2 treatment labels (Groups 1 and 2) and with 14 as the number of subjects per block
and 1 as the number of blocks. Two subjects (Group 2) were removed from the generated list in
order to obtain a randomisation of 12 subjects, with 5 subjects in Group 1, and 7 subjects in Group 2.
The randomisation list (1 to 14, with 2 subjects/numbers in Group 1 removed) was renumbered from 1
to 12 in order to correspond to the list of ponies (n = 12).
Each group was numbered A1 to A5 for Group 1 and B1 to B8 for Group 2 (organised by
increasing arithmetic ID). The online randomisation generator (www.randomization.com) was used,
with 2 treatment labels (room 1 and 2), 6 as the number of subjects per block and 1 as the number of
blocks. This procedure was repeated for Group 2 ponies, with 8 as the number of subjects per block
and 1 as the number of blocks. Room #1 contained 5 ponies (2 controls and 3 vaccinates) and room
#2 contained 7 ponies (3 controls and 4 vaccinates). The unequal pony allocation to the containment
facility rooms was motivated by the diagnosis of an early case of Sweeney disease/shoulder in one
of the ponies, shortly before infection. After veterinary examination, this pony was deemed fit to
be experimentally infected with EIV, but the number of ponies per room was altered to provide this
pony with a little bit more room (i.e., allocated to room #1, with only 4 other ponies) to minimize any
possible discomfort.
Personnel at the study site responsible for performing clinical and general health observations
or involved in laboratory assays were not informed about the allocation of individual animals at any
time during the study.
Animal welfare: This study was carried out in compliance with the UK Animals Scientific
Procedures Act 1986, with the approval of the Animal Health Trust (AHT) and MSD Animal Health
Ethics Review Committees. All procedures were conducted at the AHT. This report of clinical
trials follows the CONSORT 2010 guidelines (CONSORT Supplementary Materials Table S1 and
flow chart) [19,20].
2.2. Viruses and Experimental Infection with EIV
Viruses were all grown in embryonated hens’ eggs, purified and titrated as described
previously [21]. The EIV strain A/equine/Northamptonshire/1/13 (H3N8, Florida Clade 2 sublineage
EIV strain, passage 3 in hens’ eggs, obtained from the AHT/Horserace Betting Levy Board EI UK
surveillance scheme [7]) was used for experimental infection and was titrated in embryonated
hens’ eggs before infection (day 186). The titre was defined using the method of Reed and
Muench and expressed in logEID50 per mL [22]. The ponies were experimentally infected by
individual nebulisation 1.5 mL of an infectious EIV suspension containing a total of 107.24 EID50
EIV strain A/equine/Northamptonshire/1/13 (Flexineb® 2, Progress Equine Ltd., Hungerford, UK)
per animal [23]. The EIV strains A/equine/South Africa/4/03, A/equine/Richmond/1/07 (H3N8,
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Florida Clade 2 sublineage EIV strain) and A/equine/Northamptonshire/1/13 were used as SRH and
HI antigens.
2.3. Serology
Outcome measurement: Serum samples were collected on day-1 (V1-1 day), day 7, 14, 21, 28 (V2),
35, 42, 56, 69, 82, 110, 148, 186 (experimental infection), day 193 and day 200, and analysed by SRH and
HI assays [8] against the EIV strains A/equine/South Africa/4/03, A/equine/Richmond/1/07 and
A/equine/Northamptonshire/1/13 used as antigens. SRH antibody titres were expressed as the area
of haemolysis (mm2). An increase of at least 25 mm2 or 50% in the area of the zone of haemolysis was
regarded as significant. European Pharmacopoeia reference serum standards EU SA/4/03 Y0000712
(A/equine/South Africa/4/2003) was used as a positive control sera (data not shown). HI antibody
titres were expressed as the last dilution that inhibits chicken red blood cells haemagglutination in
presence of EIV, as previously described [24]. A titre >8 was regarded as significant and a two-fold
increase of the titre indicative of seroconversion. For statistical and graphical reasons, a HI titre <8 was
converted into 4. Values for internal reference serum standards used during the assay were within the
expected range. Serum samples were collected from all ponies on days-1 (V1-1 day) and 56, 69 and 186
(experimental infection) and analysed for tetanus toxoid-binding (ToBI) antibody titre as previously
described [25]. Tetanus toxoid (TT) antibody titres were expressed as international units (IU)/mL
of serum.
2.4. Clinical Signs of Disease (Pre-Specified Analysis)
Outcome measurement: Clinical examinations were performed daily on each pony from day
184 (2 days before infection) until day 200 (14 days after infection) for the occurrence of clinical
signs associated with EI as described previously [12,26]. Rectal temperature greater than 38.8 ◦C was
regarded as pyrexia. The total clinical score after experimental infection with EIV was calculated
using a daily score for each clinical sign according to the formula used at the AHT and reported
previously [26]:
sickness score = (2 * score RT) + score nasal discharge + score cough + 2 * (score dyspnoea +
anorexia + depression)
Ponies that developed moderate to severe and long-lasting (>3 days) clinical signs
after experimental infection with EIV were treated with potentiated sulphonamide antibiotics
(trimethoprim/sulfadiazine, TMPS) for 7 days to control secondary bacterial infection and improve
recovery, as per the ethical guidelines of the AHT.
2.5. Virus Shedding
Outcome measurement: nasopharyngeal swabs were taken from each pony one day before
infection (day 185) and daily for 14 days from days 187 to 200, with the exception of day
186 (experimental infection). Swabs were processed in 5 mL of virus transport medium (PBS,
200 U/mL streptomycin, 150 U/mL penicillin, 5 mg/mL amphotericin B and 600 mg/mL tryptone
phosphate broth, all supplied by Sigma-Aldrich Co) and stored around −70 ◦C prior to analysis by
EIV nucleoprotein quantitative reverse transcriptase polymerase chain reaction (EIV NP qRT-PCR)
or embryonated hen’s egg titration [8]. EIV NP qRT-PCR measures the presence of genetic material.
For the EIV NP qRT-PCR, automated RNA extraction was performed on 100 µL of swab sample
using a KingFisher Flex system (Fisher Scientific, Loughborough, Leicestershire, UK). Results were
expressed as number of EIV NP RNA copy per 2 µL of initial swab extract, positive results ≥100 or
≥2 if log transformed. The cut-off point (100) was determined by comparison with the EIV NP ELISA,
which was used as the gold standard diagnostic method prior to the qRT-PCR assay development.
The sensitivity and specificity of the qRT-PCR are 95.8% and 89.1%, respectively, with a cut-off threshold
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of 100 mRNA copies. The sensitivity of the assay has been favoured to maximise the surveillance for a
relatively rare infection among diagnostic sample throughput. The specificity of the qRT-PCR is likely
to be under-evaluated, which is not unusual when the new assay is superior to the gold standard
method with which it is being compared [12]. Detection of EIV shedding by qRT-PCR is referred
to in the OIE Terrestrial Manual EIV (2016), but no EIV qRT-PCR methods have been validated in
line with the OIE validation template yet [8]. Based on previous method comparisons [12,14] and
following the principles for the replacement, refinement and reduction (3Rs) of animals in research,
only samples positive by EIV NP qRT-PCR (≥2 log NP mRNA copy/2 µL nasal swab extract) were
titrated in embryonated hens’ eggs. The titration in embryonated hens’ eggs assesses the presence
of live infectious virus. Results are expressed as log EID50/mL [12,22] of swab extract as previously
described [26]. Only samples positive by EIV NP qRT-PCR (≥2 log NP mRNA copy/2 µL nasal swab
extract) were titrated in embryonated hens’ eggs.
2.6. Statistical Analysis
Statistical analyses were performed with STATGRAPHICS Centurion XVI, version 16.1.12
(StatPoint Technologies, Inc., Warrenton, VA, USA). The results of standardised skewness and
standardised kurtosis tests were used to confirm normal distribution of the data and whether the
results were distributed normally. Based on normal distribution (i.e., the results of the standardised
skewness and standardised kurtosis tests), the Student’s t-test (S) or the Wilcoxon signed rank test
(W) were used to compare the groups at specific time points. A Barnard’s test was used to compare
the need for antibiotic treatment per group (online calculator: http://scistatcalc.blogspot.co.uk/2013/
11/barnards-test-calculator.html). For each statistical test, the statistical power (S power) of the study,
with a sample size of 5 controls and 7 vaccinates and a 95% confidence interval, was controlled
with the DSS Research sample size and statistical power calculators (https://www.dssresearch.com/
KnowledgeCenter/ToolkitCalculators/StatisticalPowerCalculators). If statistical power is high (e.g.,
≥80%), the probability of making a Type II error (false negative) or concluding that there is no
difference between the groups, when in fact there is one, decreases. A statistical power ≥80% is usually
required for studies [27]. The level of significance was set as 0.05.
3. Results
3.1. Antibody Response
3.1.1. SRH Antibody Response
SRH antibody responses are presented in Figure 1. All vaccinated ponies responded to initial
immunisation (V1) and developed a detectable SRH antibody response against the antigens tested
from day 14 post V1. The intensity of the SRH antibody response varied from pony to pony
and depending on the antigen used for the assay. After the second vaccination (V2 Day 28),
the SRH antibody response was significantly increased in all vaccinated ponies when measured
between days 28 and 35 (p value = 0.022 for A/equine/Richmond/1/07, paired samples signed
rank test; 0.00004 for A/equine/South Africa/4/03, paired samples Student’s t-test, and 0.00002
for A/equine/Northamptonshire/1/13, paired samples Student’s t-test). The average (standard
deviation) SRH antibody response 14 days after V2 (onset of immunity) was 223.1 ± 16.1 mm2 against
A/equine/South Africa/4/03 (Day 35), 215.9 ± 20.7 mm2 against A/equine/Richmond/1/07 (Day
35) and 177.5.3 ± 20.0 mm2 against A/equine/Northamptonshire/1/13 (Day 35). SRH antibody titres
declined in all ponies between V2 and Day 186 (day of infection). On Day 186, all vaccinated ponies
showed detectable SRH antibody titres, with an average of 52.3 ± 11.8 mm2 against A/equine/South
Africa/4/03, 30.9 ± 10.1 mm2 against A/equine/Richmond/1/07 and 50.8 ± 14.7 mm2 against
A/equine/Northamptonshire/1/13.
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Figure 1. Individual single radial haemolysis (SRH) antibody response against A/equine/South
Africa/4/03 (a) A/equine/Richmond/1/07 (b) and A/equine/Northamptonshire/1/13 (c).
Vaccination and infection are indicated with arrows. Closed circles = vaccinated ponies; open
circles = control ponies.
All vaccinated ponies showed a statistically significant increase of SRH antibody titres
against all EIV antigens between day 186 (day of infection) and day 193 (7 days after infection,
anamnestic mem ry response of the antibod response stimulated by vaccinati ), with p values
of 0.0015 for A/equine/Richmond/1 07, 0.0016 for A/equine/South Africa/4/03, and 0.006 for
A/equine/Northamptonshire/1/13 (S). On Day 200 (14 days after infection), the average SRH
antibody titres were 178.1 ± 32.4 mm2 against A/equine/Richmond/1/07, 190.2.1 ± 28.3 mm2 against
A/equine/South Africa/4/03 and 190.1 ± 35.5 mm2 against A/equine/Northamptonshire/1/13.
None of the control ponies had measurable SRH antibody titres prior to experimental i fection
with A/equine/Northamptonshire/1/13. Overall, results from control ponies confirmed the absence of
contact with naturally-circulating EIV during the study. Fourteen days after experimental infection with
A/equine/Northamptonshire/1/13 (day 200), all of the control animals seroconverted to the H3N8
EIV HA antigens. The average SRH antibody titres were 175.4 ± 13.6 mm2 against A/equine/South
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Africa/4/03, 161.0 ± 14.8 mm2 against A/equine/Richmond/1/07 and 192.0 ± 25.1 mm2 against
A/equine/Northamptonshire/1/13.
On day 200 (14 days after infection), the titres of SRH antibodies in the control
and vaccinated groups were not statistically different, when tested against A/equine/South
Africa/4/03 (p value = 0.31, S), A/equine/Richmond/1/07 (p value = 0.86, W) or against
A/equine/Northamptonshire/1/13 (p value = 0.92, S).
3.1.2. HI Antibody Response
Haemagglutination inhibition antibody titres against at least one antigen were detected in 6 out
of 7 vaccinated ponies after V1. After the second vaccination (V2 day 28), the HI antibody response
against at least one antigen was significantly increased in all of the vaccinated ponies (day 28 and
day 35 comparison: p value = 0.002 for A/equine/South Africa/4/03, paired sample signed rank
test; p value = 0.011 for A/equine/Richmond/1/07, paired Student’s t-test; p value = 0.003 for
A/equine/Northamptonshire/1/13, paired Student’s t-test). The intensity of the HI antibody response
varied from pony to pony and depending on the antigen used for the assay. When tested on day
186 (day of infection), 6 out of the 7 vaccinated ponies had measurable HI antibody titres against at
least one antigen. There was a significant increase in the HI antibody titres (on Day 194 or Day 200,
depending of the pony and antigen tested) in all of the vaccinated ponies after experimental infection
with A/equine/Northamptonshire/1/13 (Figure 2).
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There were no measurable HI titres in any of the control ponies during the vaccination phase
of the study (day-1 to day 186). All of the control po ies seroconverted to at least one antigen
after experime tal infection with A/equine/Northamptonshire/1/13, but overall HI titr s remained
low. On day 200, the HI antibody titres against A/equi e/Richmond/1/07 (p value = 0.0014,
S), A/equine/Sout Africa/4/03 (p valu = 0.0006, S) or A/equine/Northamptonshire/1/13
(p value = 0.004, W) in th vaccinated group were statistically significantly higher than in the
control group.
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3.1.3. TT Antibody Response
Tetanus toxoid (TT) antibody titres are presented in Table 2. There were no TT antibody titres
on day-1. Tetanus antibody antibody titres were measured in all of the vaccinated ponies on Day
56 (52.1 ± 21.0 IU/mL) but none of the unvaccinated control ponies had TT antibody titres. All of the
ponies enrolled in the study were administered anti-tetanus serum administration on day 61 or day
62 (castration of male ponies). On day 69 (around one week after anti-tetanus serum administration),
TT antibody titres were measured in all of the ponies (25.7 ± 11.3 IU/mL and 0.33 ± 0.15 IU/mL in the
vaccinated and control groups, respectively). On day 186 (day of infection), TT antibody titres were
measured in all of the vaccinated ponies (3.2 ± 1.2 IU/mL) but not in control ponies.
Table 2. Tetanus toxoid antibody titres, expressed as international units (IU)/mL.
Pony # Group Day-1 Day 56 Day 69 Day 186 *
1 Vaccinates 0.0 57.31 42.15 4.43
2 Vaccinates 0.0 76.13 38.39 4.75
3 Vaccinates 0.0 51.00 16.14 2.69
4 Vaccinates 0.0 60.19 24.34 2.30
5 Vaccinates 0.0 44.42 13.35 3.85
6 Vaccinates 0.0 65.32 28.63 1.36
7 Vaccinates 0.0 10.30 16.78 3.01
8 Controls 0.0 0.0 0.58 0.0
9 Controls 0.0 0.0 0.36 0.0
10 Controls 0.0 0.0 0.18 0.0
11 Controls 0.0 0.0 0.27 0.0
12 Controls 0.0 0.0 0.28 0.0
average Vaccinates 0.0 52.1 25.7 3.2
STDV Vaccinates 0.0 21.0 11.3 1.2
average Controls 0.0 0.0 0.33 0.0
STDV Controls 0.0 0.0 0.15 0.0
* Day 186: day of infection by individual nebulisation.
3.2. Clinical Signs of Disease after Experimental Infection with A/Equine/Northamptonshire/1/13
Vaccination significantly reduced the clinical signs of disease induced 158 days (approximately
22.5 weeks) after the second immunisation by an experimental infection with the EIV strain
A/eq/Northamptonshire/1/13. The vaccinated group had a significantly lower cumulative clinical
score and average clinical score per day. Pyrexia was recorded in 4 out of 5 control animals for
2 to 4 days and 1 out of 7 vaccinates for 1 day. Significant differences were also observed for nasal
discharge and coughing, with lower occurrence and severity in the vaccinated animals than in the
controls. There was no difference in ocular discharge scores between the control and vaccinated groups.
The results are reported in Table 3 and Figure 3.
Four out of five control ponies received antibiotic treatment on day 194 (8 days after
experimental EIV infection) in order to control secondary bacterial infection and to improve recovery
(trimethoprim/sulfadiazine, for 7 days). None of the vaccinated ponies required antibiotic treatment.
There was a statistically significant difference in the number of animals treated with antibiotics per
group (p value = 0.000482; Barnard’s test). In order to take into account the potential effect of antibiotic
treatment on the clinical signs of disease, a reduced statistical analysis from the day of infection (day
186) up to the first day of treatment (day 8 after infection) was also performed. Results are presented
in Table 3. The statistical power of the study was sufficiently high (≥80%) for all parameters except the
average of the severity score for nasal discharge per day and the average of the cumulative score for
ocular discharge due to individual variability within a group.
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Table 3. Clinical signs (mean ± SD) of disease after experimental infection with A/equine/
Northamptonshire/1/13 and statistical analyses (vaccinated group versus control group). Significant
differences are in bold text. Reduction (%, SD) = the reduction in clinical signs in the vaccinated
group compared to the control group, A = analysis, S power = statistical power. * Student’s t-test;
** Wilcoxon’s test; *** Barnard’s test.
Clinical Sign Controls Vaccinates Normal A 1 Reduced A 2 S Power
Cumulative clinical score 47.0 ± 9.8 9.6 ± 5.1 0.000006 * 0.00006 * 100%
Clinical severity score per day 3.9 ± 0.5 2.0 ± 0.9 0.006 ** 0.004 * 99.9%
Disease duration (days) 12.0 ± 2.0 4.1 ± 2.2 0.00009 * 0.004 ** 100%
Pyrexia duration (days) 1.0 ± 0.7 0.1 ± 0.4 0.033 ** 0.033 ** 82.7%
Frequency of pyretic ponies 4/5 (80%) 1/7 (14.3%) 0.032 *** na na
Cumulative nasal discharge score 25.6 ± 5.9 7.9 ± 4.2 0.0001 * 0.005 ** 100%
Nasal discharge severity score per day 2.5 ± 0.1 2.0 ± 1.0 0.14 * 0.04 ** 37%
Nasal discharge duration (days) 10.2 ± 2.8 3.4 ± 1.9 0.0005 * 0.001 * 99.9%
Cumulative cough score 19.6 ± 6.8 1.3 ± 3.0 0.005 ** 0.004 ** 100%
Cough severity score 1.3 ± 0.5 0.1 ± 0.2 0.005 ** 0.005 ** 100%
Cough duration (days) 8.8 ± 2.2 0.9 ± 1.9 0.004 ** 0.00003 * 100%
Cumulative ocular discharge score 0.6 ± 0.9 0.4 ± 0.8 0.73 * 0.45 * 10.6%
1 From the day of infection and up to day 14 after infection. 2 from the day of infection and up to the first day of
antibiotic treatment.
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Figure 3. Cum lative clinical signs of disease. y of infection (C; Day 186 = C-0) is indicated with
an arrow. Closed circles = vaccinated ponies; circles = control ponies. The period of antibiotic
treatment (trimethoprim/sulfadiazine, T PS) is represented as a shaded area. The time periods
considered for the normal and the reduced analyses are also indicated.
3.3. Virus Shedding after Experimental Infection with A/Equine/Northamptonshire/1/13
All of the control and vaccinated ponies were positive for EIV shedding after experimental
infection with A/equine/Northamptonshire/1/13 when measured by EIV NP qRT-PCR. The EIV NP
mRNA copy number/2 µL of nasal swab extract and the number of days positive are presented in
Supplementary Materials Table S2. Results for days 183 (3 days before infection) to 200 (14 days after
infection/challenge) are illustrated in Figure 4. Control ponies shed EIV from day 188 (2 days before
infection/challenge) to day 195 (9 days after infection), with an average duration of 6.6 ± 0.9 days.
EIV shedding was measured in vaccinated ponies from day 187 (1 day after infection) to day
193 (7 days after infection), with an average duration of 4.7 ± 1.01 days. All of the control ponies
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and 5 out of 7 vaccinated ponies were positive for EIV shedding after experimental infection with
A/equine/Northamptonshire/1/13 when titrated in embryonated hen’ eggs. Control ponies shed
infectious EIV from day 188 (2 days after infection) to day 192 (6 days after infection), with an average
duration of 3.2 ± 1.8 days. Infectious EIV shedding was measured in vaccinated ponies from day
188 (2 days after infection) to day 191 (5 days after infection), with an average duration of 1.4 ± 0.8 days.
The duration of EIV shedding (as measured by qRT-PCR or titrated in embryonated hens’ eggs) was
significantly shorter in vaccinated ponies than in control ponies (p = 0.006 and p = 0.04, respectively, S,
Supplementary Materials Table S2). The statistical power of the study was sufficiently high (≥80%)
for all parameters except the average titre per day of EIV shedding (qtPCR and embryonated hens’
eggs) average of the cumulative shedding of EIV (embryonated hens’eggs) and average duration of
EIV shedding (embryonated hens’eggs) due to individual variability within a group.Vaccines 2018, 6, x 11 of 17 
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Figure 4. Virus shedding measured by equine influenza virus (EIV) NP qRT-PCR (a) or embryonated
hens’ eggs titration (b) and coughing score. The day of infection (C; day 186 = C-0) is indicated with
an arrow. Closed circles = EIV shedding measured in NS from vaccinated ponies; open circles = EIV
shedding measured in NS from control ponies; dotted line = coughing score for vaccinated ponies;
broken line = coughing score for control ponies. The dotted line (a) represents the threshold above
which a sample is considered positive for EIV by qRT-PCR. Only samples which tested positive by EIV
NP qRT-PCR (≥2 log NP mRNA copy/2 µL nasal swab extract) were titrated in embryonated hens’
eggs. Other samples (< l RNA copy/2 µL nasal swab extract) were consi ered neg tive and
repres nted as uch (b).
Vaccines 2018, 6, 38 12 of 17
4. Discussion
The vaccine efficacy study reported here was specifically designed to test the protection of horses
induced by a commercially available EI vaccine under unfavourable conditions. For this purpose,
two major elements were taken into consideration: (1) the timing of the experimental infection (i.e.,
infection 158 days after second immunisation (V2)) and (2) the nature of the EIV strain used for this
purpose (i.e., recent FC2 EIV strain) in relation to the EI vaccine strains (i.e., FC1 EIV and European
lineage strains). A previous study has shown that ponies vaccinated with an ISCOM-based EI vaccine
and experimentally infected with EIV only 78 days after V2 were significantly protected against
clinical signs of equine influenza but virus shedding, while significantly reduced, was still sufficient to
effectively transmit EI to sentinel ponies for up to 6–8 days after experimental infection [14].
Virus excretion was measured using both detection of mRNA (qRT-PCR) and infectious EI
(titration in embryonated hens’ eggs). This design could have been strengthened further using sentinel
naïve ponies to determine if the amounts of infectious virus excreted by vaccinated ponies were
sufficient to actively transmit EI, as shown previously [14]. Antibody titres were measured using
HI and SRH assays in the present study. While the former is based only haemagglutinin, SRH
(a complement fixing assay) targets both haemagglutinin and neuraminidase. Neuraminidase plays
an increasingly recognised role as an influenza immunogen, through reducing the amount of virus
released from infected cells [28]. In humans, antibodies to both haemagglutinin and neuraminidase
can help to predict immunity to influenza and reduce influenza-associated disease [29]. It remains
to be demonstrated whether antibodies to neuraminidase also play a key role in protection against
influenza in horses [28,29].
The EI vaccine used in this study (i.e., Equilis Prequenza-Te) contains whole EIV strains
A/equine/South Africa/4/03 (H3N8, American lineage, Florida Clade 1 sublineage, isolated in
2003) and A/equine/Newmarket/2/93 (H3N8, European lineage, isolated in 1993). This vaccine
is considered to be partially updated in relation to the most recent OIE ESP recommendation on EI
vaccine strain composition that supports the inclusion of representative EIV strains from both FC1 and
FC2 sublineages [30]. The challenge strain A/equine/Northamptonshire/1/13 used in this study is
a recent FC2 strain (isolated in 2013) that presents significant differences in the nucleotide sequence
encoding HA from the FC1 EIV vaccine strain A/equine/South Africa/4/03 [7] (Supplementary
Materials Figure S1). Antigenic differences in HA between circulating, vaccine and reference EIV
strains are usually evaluated using the HI assay in combination with a panel of EIV-specific ferret
antisera, supported by antigenic cartography of HI data and genetic sequencing of the haemagglutinin
1 (HA1) gene. The HI titres in ferrets against A/equine/Northamptonshire/1/13 were 5.7 to 8-fold
lower than those raised against A/equine/South Africa/4/03 (vaccine strain) and comparable
to HI titres obtained with ferret anti-sera against A/equine/Richmond/1/07 or the more recent
A/equine/Devonshire/1/11 (closely related to A/equine/Northamptonshire/1/13), respectively [7].
Such differences in HI titres are related to the antigenic diversity in the HA sequence between
FC2 strains such as A/equine/Northamptonshire/1/13 and FC1 strains, such as A/equine/South
Africa/4/03. These antigenic differences form the basis for the OIE ESP recommendations to include
both FC1 and FC2 EIV strains in EI vaccines.
The immunogenicity of EI vaccines is based on the type and amount of antigen and the adjuvant,
which enhances and modulates the immune response and targets antigen to antigen-presenting cells,
thus stimulating both humoral and cell-mediated immunity. This helps to explain why EI vaccines
induce far higher and serotypically broader protection than the vaccines used to immunize humans
against seasonal influenza. This may also perhaps explain why confirmed vaccination breakdown—the
sudden appearance of disease in an individual or herd in which immunity had previously appeared or
been assumed to be adequate—is relatively infrequent in horses that are regularly and appropriately
vaccinated against EIV [6,24]. Protecting the equine population against EIV is complex. There can be
considerable individual variation in response to vaccination during field use, depending on a number
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of factors, including the innate immune system but also age and stress (training, diet changes, transport,
etc.) [31]. Immunisation is at its most effective when a high level of the population is covered.
The experimental infection in the present study was performed 158 days (around 5.2 months)
after V2, at a time when the first revaccination (V3) is recommended (subsequent revaccinations would
usually take place every 12 months). This specific timing was selected to maximise the susceptibility
of vaccinated ponies to EIV infection (i.e., immunity gap). Under these conditions (i.e., combination
of EIV strain heterogeneity and immunity gap), immune responses induced by EI vaccination was
placed under significant pressure and tested using the natural host model commonly used to evaluate
EI vaccine efficacy.
Clinical signs of disease were significantly reduced in vaccinated ponies when compared with
unvaccinated control ponies, despite SRH antibody titres being below the threshold proposed for
protection against clinical signs of disease induced by experimental infection (i.e., 85 mm2 against
homologous EIV strain) [9,10]. There was a notable reduction in pyrexia, which confirms the animal
welfare benefits of vaccination. The dramatic reduction in coughing in the vaccinated ponies compared
to the controls is likely to help to reduce the risk of EIV dissemination and disease transmission. Nasal
discharge usually evolves after experimental infection with EIV, with an increase in magnitude (from
mild to copious discharge) and nature (from serous discharge in the first few days after viral infection
becoming mucopurulent due to the establishment secondary bacterial infection). While this clinical
marker was less affected by vaccination, there was a statistically significant reduction in the need
to use antibiotics to prevent and/or control secondary bacterial infection in the vaccinated group
compared to the controls. A canarypox-vectored EI vaccine and ISCOMatrix-adjuvanted EI vaccines
have been previously shown to protect against the EIV strains A/equine/Sussex/89, /Kentucky/91
and /Kentucky/9/95, during the immunity gap (experimental infection 5–6 months after V2) [32–34].
However, heterogeneity between vaccine and challenge strains was limited in these studies. Despite
the significant time between V2 and the experimental infection (i.e., 158 days), the clinical outcome
measured in the vaccinated group in the present study was similar to the outcome measured in ponies
vaccinated with (1) an EI vaccine based on a canarypox-vectored vaccine expressing the haemagglutinin
gene of EIV and experimentally infected with EIV 14 days after the second immunisation [35] and (2) a
whole inactivated EI vaccine as well as experimental infection with EIV 14 or 15 days after V2 [12,26].
The clinical protection achieved in the current study was also similar or superior to the one recorded in
ponies vaccinated with an ISCOM-based EI vaccine and experimentally infected with EIV 14 days [25]
or 78 days after V2 [14], respectively.
There was little or no difference in the amount of EIV shed measured between control and
vaccinated ponies during the first few days after experimental infection. This is likely to be a
consequence of the detectable but limited amount of EIV HA-specific antibodies measured at the time
of infection, being high enough to provide clinical protection but insufficient to completely prevent
EIV infection. Previous studies have clearly illustrated a correlation between SRH antibody titres
and protection [9,10] but high levels of SRH antibody are necessary to provide sterilising immunity
and prevent EIV infection (sterilising immunity is usually characterised by an absence of clinical
signs of disease, virus shedding and seroconversion subsequent to experimental infection). Sterilising
immunity can be observed shortly after V2. While it has not been demonstrated experimentally,
sterilising immunity may also occur at peaks of immunity induced by subsequent boost immunisations
(V3, V4, etc.) [35]. It is important to note that the infectious dose was delivered by individual
nebulisation, which significantly increases the amount of virus inhaled by ponies when compared
with the historical room nebulisation procedure previously used in numerous EI vaccine studies.
Unvaccinated and unprotected control ponies also shed significant amount of EIV and could be
considered as a secondary source of infection (i.e., during the infectious phase of the study, vaccinated
and control ponies were commingled with at least 2 control ponies in each room). Under these
conditions, low levels of immunity on day 186 may have been overcome, resulting in no or little
difference in virus shedding between vaccinated and control ponies immediately after experimental
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infection. However, EIV shedding quickly subsided in the vaccinated ponies when compared to
the control animals. This observation supports a rapid mobilisation and anamnestic response of
EIV-specific immunity induced by vaccination, as early as 4 days after infection, confirmed by
seroconversion measured 7 days after experimental infection in the vaccinated ponies. This result
clearly highlights the benefit of EI vaccination. Such an effect is usually not measurable in clinical trials
with experimental infection set up at the onset of immunity conferred by vaccination (i.e., experimental
infection 2 to 3 weeks after primary immunisation (V1 and V2)). Under such conditions, antibody titres
present at the time of experimental infection are usually high enough to significantly limit initial EIV
infection, which immediately impacts and reduces the amount of virus shed and detected [12,25,26,35].
Prior to V1, no antibodies against tetanus were detected. Unvaccinated control ponies remained
negative throughout the study, except one week following tetanus antiserum administration when the
titre was 0.33 ± 0.15 IU/mL. In vaccinated ponies, tetanus antibody titres were 52.1 ± 21.0 IU/mL
one month following V2, 25.7 ± 11.3 IU/mL around 6 weeks after V2 (one week following tetanus
antiserum administration) and 3.2 ± 1.2 IU/mL around 22.5 weeks (158 days) after V2. This is similar
to the tetanus antibody titres measured in a previous study with an older version of this vaccine [36].
In that study, tetanus antibody titres were over 20 IU/mL 2 weeks after V2 and around 2 IU/mL
at 22 weeks after V2 followed by lower levels (0.31 IU/mL) that were maintained for at least until
76 weeks after V2 and V3 has been shown to result in even higher tetanus antibody titres in horses
that provide protection until the time of the next recommended annual revaccination [36]. These
titres are far above those required for clinical protection (ToBI titre of 0.02 IU/mL)[37]. In a study in
client-owned horses, tetanus antibody titres (ToBI) remained above 0.04 IU/mL (limit of detection of
assay) for 12 months (25/26 horses), 24 months (16/16) or 36 months (8/8) after V3 [38]. These studies
support protection of horses against tetanus for at least 17 months after the primary vaccination course
and 24 months after the first revaccination with this vaccine. Based on the rather slow decrease of ToBi
titers, it is clear that the protective titer may last even longer than observed in these studies [36]. As a
consequence of the 24-month duration of immunity against tetanus, an alternating annual vaccination
schedule consisting of an EI vaccine and a combined EI and tetanus vaccine is proposed after V1, V2
and V3 of a combined EI and tetanus vaccine [36].
In the event of an outbreak, and if there is an imminent risk of contact with EIV, boost EI
vaccination may need to be considered, especially for horses where the immunisation schedule has been
started recently [39]. While a shortening of the interval between V1 and V2 has been tested [25,40,41],
an attempt to reduce the gap between V2 and V3 has been shown to be counter-productive, with a
long term detrimental effect on humoral immunity induced by V3 and V4 boost immunisations [17].
This may mean that with current EI vaccine technology it is not possible to close the immunity gap
and certainly reducing the interval between V2 and V3 is not recommended.
5. Conclusions
In the present study, the whole inactivated EI and tetanus vaccine (Equilis Prequenza Te) provided
good clinical protection against a recent EIV strain, even when challenged 158 days after V2. All of the
vaccinates had detectable but low SRH antibody titres at the time of experimental infection. The clinical
protection demonstrated in the present study was similar to what has been observed for other EI
vaccines when tested much sooner after immunisation, such as at the onset of immunity [12,25,32,42,43]
or 2.5 months after V2 [14]. Virus shedding was measured after individual challenge by nebulisation
in the present study, but the overall duration was significantly reduced in the vaccinates compared to
the unvaccinated control ponies. This study illustrates that ponies immunised with this EI and tetanus
vaccine (Equilis Prequenza Te) show limited evidence of the immunity gap when experimentally
infected 158 days (around 5.2 months) months after V2 with a recent heterologous strain, which is
representative of the EIV strains circulating in the EU.
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